Cytosar-U, Cytarabine News

Sunesis Pharmaceuticals, Inc. today announced that the independent Data and Safety Monitoring Board for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as planned without changes to study conduct.

Celator Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing new and more effective therapies to treat cancer, today announced that a new analysis of data from two randomized Phase 2 studies of CPX-351 Liposome Injection in patients with acute myeloid leukemia has confirmed the consistent activity of CPX-351 and identified ... (more)

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the Journal of the American Society of ... (more)

Acute myeloid leukemia , the second most common form of leukemia in children, is a blood cancer in which the bone marrow makes a large number of abnormal white blood cells that crowd out other healthy blood cells over time, leading to infection, anemia, or excessive bleeding.

Eutropics Pharmaceuticals Inc. announced today that Eutropics and The University of Texas MD Anderson Cancer Center will present results from a clinical study employing Eutropics' proprietary PraediCare Dx assay to discriminate therapeutic response in acute myeloid leukemia patients to standard-of-care-based chemotherapy.